Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regeneron Pharmaceuticals

589.48
-8.6800-1.45%
Post-market: 587.92-1.5643-0.27%19:50 EDT
Volume:1.44M
Turnover:855.81M
Market Cap:63.64B
PE:14.86
High:610.45
Open:602.35
Low:585.50
Close:598.16
52wk High:1,211.20
52wk Low:476.49
Shares:107.97M
Float Shares:100.00M
Volume Ratio:1.42
T/O Rate:1.44%
Dividend:1.76
Dividend Rate:0.30%
EPS(TTM):39.67
EPS(LYR):40.90
ROE:15.34%
ROA:6.66%
PB:2.13
PE(LYR):14.41

Loading ...

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Aug 22

Regeneron Pharmaceuticals Inc. Stock Rallies 3.4%, Outperforms Competitors

Dow Jones
·
Aug 21

BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EDT on 2025-08-20

Reuters
·
Aug 21

BUZZ-Regeneron rises after FDA's extended decision date for eye drug comes ahead of expectations

Reuters
·
Aug 21

BUZZ-U.S. STOCKS ON THE MOVE-Snowflake, silver miners, oil firms

Reuters
·
Aug 21

FDA Extends Review Period for Regeneron Pharmaceuticals' EYLEA HD® Prefilled Syringe and Expanded Label Submissions to Q4 2025

Reuters
·
Aug 20

Eylea Hd® (Aflibercept) Injection 8 Mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension

THOMSON REUTERS
·
Aug 20

Regeneron Pharmaceuticals Inc - FDA Extends Target Action Dates for Eylea Hd to Q4 2025

THOMSON REUTERS
·
Aug 20

Regeneron Pharmaceuticals Inc - FDA Extended Review Due to Major Amendment From Third-Party Inspection

THOMSON REUTERS
·
Aug 20

Regeneron Pharmaceuticals Inc: Eylea Hd Remains Available in U.S. Through Vial Administration

THOMSON REUTERS
·
Aug 20

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Aug 16

How Will Regeneron’s (REGN) Solid Earnings and R&D Progress Shape Its Risk-Reward Balance?

Simply Wall St.
·
Aug 15

Top Calls on Wall Street: Nvidia, Amazon, Microsoft, AMD, CoreWeave, Li Auto, Cisco, and More

Tiger Newspress
·
Aug 14

BioLineRx Ltd. Reports Q2 2025 Revenues of $0.3M, Down from 2024; Cash Runway Extended to H1 2027

Reuters
·
Aug 14

Regeneron initiated with a Buy at Rothschild & Co Redburn

TIPRANKS
·
Aug 14

Cantor Fitzgerald Reaffirms Their Buy Rating on Regeneron (REGN)

TIPRANKS
·
Aug 14

Metagenomi Inc. Appoints Dr. Laurence Reid to Board of Directors, Bolstering Biotech Leadership Team

Reuters
·
Aug 12

Truist Securities Adjusts Regeneron Pharmaceuticals Price Target to $812 From $940, Maintains Buy Rating

MT Newswires Live
·
Aug 11

Truist Financial Reaffirms Their Buy Rating on Regeneron (REGN)

TIPRANKS
·
Aug 11

Regeneron Pharmaceuticals Inc. Releases Transcript of Q2 2025 Earnings Call

Reuters
·
Aug 09